ABSTRACT OBJECTIVES: To investigate patterns of survival among brain cancer patients in Canada.
T
here is little information available on brain tumour incidence and survival among the Canadian population. 1, 2 Available information provides an overall estimate of brain cancer survival without an assessment of patterns by age, sex, region or tumour subtype; these patterns may be influenced by clinical and policy decisions regarding treatment. It is not well recognized by the general population that there is wide variation in the prognosis of patients with brain cancers, depending on the tumour histology type, patient and clinical features, all of which may influence diagnosis and treatment. Based on information from many other countries, [3] [4] [5] [6] [7] it is well established that early age at diagnosis is associated with better prognosis for patients with these tumours, largely because the histology types that occur most frequently in younger age groups have a less aggressive nature. Mao 8 demonstrated an improvement in brain cancer survival rates in the Canadian province of Saskatchewan between 1967 and 1986 that was primarily due to survival improvement in patients under the age of 65. The objective of our study is to investigate survival patterns by region and histology among Canadian patients with malignant brain tumours diagnosed between 1992 and 2008, while adjusting for age and sex. Due to the regional nature of health care systems and health care guidelines in Canada, some provincial differences are expected to emerge. This information will allow health care providers and researchers to explore the reasons underlying regional differences in survival rates and make evidence-informed decisions about clinical guidelines and health care policy with this patient population.
METHODS

Cohort selection
Data were acquired after the combined approval of Statistics Canada and the University of Alberta's ethics board. Administrative data were obtained from the Canadian Cancer Registry (CCR, 2012 release) for patients with brain tumours (International Classification of Disease for Oncology (ICD-O) 2 nd and 3 rd edition topography codes C700-C729 and C751-C753) who were diagnosed between 1992 and 2008 across all Canadian provinces and territories. We excluded patients whose brain tumours are non-malignant (ICD-O-2/3 behaviour code 0/1/2, n = 10,970) and whose chronologic sequence numbers of multiple primaries are not one (CCR code TD2, n = 2185). Thus our cohort consists of patients with first-ever primary malignant brain cancer diagnosis between 1992 and 2008. Survival time is the outcome of interest and age, sex, geographical region, diagnostic method and tumour histology were independent variables. We collapsed some regions together due to small sample size: the Atlantic provinces (New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador), the Territories (Northwest Territories, Nunavut and Yukon) and two Prairie provinces (Manitoba and Saskatchewan). We used CCR code T25 to categorize diagnostic methods broadly into "microscopically confirmed" and "non-microscopically confirmed" for patients diagnosed between 2004 and 2008. For patients diagnosed between 1992 and 2003, categories (CCR code T11) include "radiology or laboratory diagnosis other than histology, autopsy and cytology", "Surgery (without histology), or clinical diagnosis", "death certificate only" and "method of diagnosis unknown", all of which are classified as "nonmicroscopically confirmed". Histology types were grouped according to codes outlined by the Central Brain Tumor Registry of the United States (CBTRUS), 9 and the following seven histology types were selected for detailed analysis based on having 800 or more cases: glioblastomas (GBM), diffuse astrocytomas, gliomas (not otherwise specified) -hereinafter referred to as gliomas (NOS), oligodendrogliomas, anaplastic astrocytomas, oligoastrocytic tumours, and anaplastic oligodendrogliomas. All other histology types are collapsed into the "all others" category as an eighth histology type category. Since the proportional hazard (PH) assumption does not hold for the variable age group for any histology type, age-stratified Cox PH models were fitted for each histology type to estimate the adjusted hazard ratios for regions. However, the stratification increases the uncertainty in the estimation of model-based survival rates. To obtain unbiased and efficient model-based age-, sex-and regionspecific 5-year survival rate estimates, separate time-specific generalized linear models were used for each of the histology types. 11, 12 Our primary analyses used all cases regardless of their diagnosis method.
Data analysis
Estimates for territories were not reported from the crude KaplanMeier and model-based analyses due to their small sample sizes. Survival estimates for the <20 years age group from the modelbased analyses were not reported, in order to concentrate on the Canadian adult population. All analyses were performed using statistical software SAS 9.4 (SAS Institute, Cary, NC) and R 3.1.3. 13 All frequencies and proportions presented are subject to rounding in accordance with Statistics Canada requirements.
RESULTS
A total of 38,095 patients were diagnosed with first-ever primary malignant brain tumours between 1992 and 2008 in Canada. There is no improvement in survival rates over time during the study period (data not shown). The frequencies and the corresponding observed deaths are summarized in Table 1 for age groups, sex, regions and diagnostic method. Tumours occurred more frequently in males (56%) than in females (44%), and in older than in younger age groups. Patients over the age of 65 years accounted for 37% of the study population and 46% of deaths, while those under age 20 years made up 11% of the study population and accounted for less than 5% of the deaths. The frequency of patients by region reflected the population size in each province; the largest proportion of patients were diagnosed in Ontario (39%) and Quebec (26%), followed by British Columbia (12%). Manitoba and Saskatchewan combined accounted for 7.0% of brain cancers.
Histology type-specific incidence, death and 1-, 2-and 5-year survival estimates are shown in Table 2 . The most common histology was GBM (37%) followed by diffuse astrocytomas (15%). In descending order, the estimated 5-year survival rates are: 65% (95% CI: 62.5%-67.4%) for oligodendrogliomas, 46% (95% CI: 42.6%-49.3%) for oligoastrocytic tumours, 41.5% (95% CI: 37.9%-45.0%) for anaplastic oligodendrogliomas, 33.9% (95% CI: 31.6%-36.2%) for gliomas (NOS), 26.6% (95% CI: 25.4%-27.8%) for diffuse astrocytomas, 18.2% (95% CI: 15.8%-20.7%) for anaplastic astrocytomas, and 4.0% (95% CI: 3.7%-4.3%) for GBM. Figure 1 displays histology type-specific Kaplan-Meier survival curves for brain cancer patients. Long-term prognosis was best for patients with oligodendrogliomas and all other tumours, and poorest for patients with GBM. Survival curves show a poor survival experience within the first few years of diagnosis for gliomas (NOS), diffuse astrocytomas, anaplastic astrocytomas and GBM, and a better survival experience for oligoastrocytic tumours, anaplastic oligodendrogliomas, oligodendrogliomas and all other tumours. The region-specific Kaplan-Meier survival curves are shown in supplementary materials (Supplementary Figure A -see ARTICLE TOOLS section on journal website). Using Ontario as the reference province, the adjusted hazard ratio estimates of regions are shown in Figure 2 for the eight histological types. The patterns of hazard ratios were not consistent by region across the histology types. Compared to Ontario, the estimated hazard rates were significantly higher in all other provinces for GBM and diffuse astrocytomas (p < 0.001), and higher for gliomas (NOS) in British Columbia, Alberta and the Atlantic provinces (p < 0.01). Hazard rate estimate was significantly higher for anaplastic astrocytomas in Quebec (p < 0.05), for oligoastrocytic tumours in British Columbia (p < 0.01), and for all other tumours in British Columbia, the Atlantic provinces and the Prairie provinces (p < 0.01) when compared to Ontario. Estimated hazard rates were significantly lower for anaplastic oligodendrogliomas in Quebec (p < 0.05) and marginally lower for oligoastrocytic tumours in the Atlantic provinces (p < 0.10) when compared to Ontario. When we restricted the analyses to microscopically-confirmed cases only, the regional survival patterns remain largely unchanged in all histology types except for gliomas (NOS) and "all others". Table 3 shows 5-year region-, age group-and sex-specific survival rate estimates for selected histology types -i.e., excluding the gliomas (NOS) and "all others" -obtained from the time-specific generalized linear models using all cases. The estimates for gliomas (NOS) and "all others" were not provided because we observed large discrepancy between estimates from the all-case analysis and the microscopically-confirmed cases only analysis. Survival estimates were significantly higher for females than for males in all histology groups with the exception of GBM and anaplastic oligodendroglioma, where survival rate differences by sex were not statistically significant. Estimated survival decreased significantly as age-at-diagnosis increased from 21-44 years to 45-64 years, and to 65 years and over, in all histology groups studied. Compared to Ontario, the age-and sex-adjusted 5-year GBM survival estimates were lower in British Columbia, Alberta and the Prairie provinces (p < 0.01), and lower in the Prairies for anaplastic astrocytomas (p < 0.05). Survival estimates were significantly higher for oligodendrogliomas in Alberta (p < 0.001), and for anaplastic oligodendrogliomas in Alberta and Quebec (p < 0.05). The patterns of these 5-year survival rates by province(s) were similar but not the same when compared to the patterns of hazard rates by province(s) estimated from the Cox proportional hazard model. This is to be expected, as the Cox model assumes proportion hazard throughout the entire follow-up time while the time-specific generalized linear model takes a snap shot of the survival status at 5 years post diagnosis. Repeating Table 3 restricted to microscopically-confirmed cases provided estimates that were similar to those reported here, except for diffuse astrocytomas of all age groups in Quebec and oligoastrocytic tumours for age group 45-64 in Quebec and the Prairie provinces (lower by 2 percentage points or more in the microscopically-confirmed cases only analysis).
DISCUSSION
As expected, observed brain cancer survival rates tend to be higher in females than in males and in younger than in older age groups. These data are limited to patients with malignant brain tumours. Information on non-malignant tumours has not historically been available in most provinces, 1 so survival rates for these tumour categories await the accrual of prospective data. Survival and hazard rate patterns by region and histology type suggest that there may be a number of underlying reasons for variation. There are known differences in how Quebec vs. other provinces records date of diagnosis, 14 but we anticipate this survival underestimate to be rather small in the context of the long-term rates presented. It is possible that variation in clinical presentation, diagnostic classification, patient care and treatment decisions (by the patient, the physician and/or due to system differences) may explain some of the variation in provincial rates. No treatment variables were available in the CCR data, which is a limitation of the data sources. Thus we were not able to assess its effect on survival and whether it confounds the relationship of survival rate and region. Other clinical factors, including tumour size and other prognostic factors, have not been considered in this analysis. We know that the health care system is driven by provincial policy and that clinical guidelines and chemotherapy drug coverage vary across provinces, factors that will be indirectly reflected in these data. For example, in current clinical practice, Avastin is a relatively new drug used for GBM treatment that is covered by insurance in Manitoba but not in Alberta. We also know that factors in the cancer care continuum may be present, such as access to primary care, access to medical specialist and/or Table 3 .
Estimated five-year survival probability (95% confidence interval) for selected histology types by region, age group, and sex when sex effect is significant (p < 0.05),* based on all cases (including non-microscopically confirmed) technology, delay in the referral process during cancer diagnostics and/or treatment phase, lack of care coordination, and adherence to treatment guidelines. Similar regional variation for other cancers in health care has been reported in Canada, the Netherlands and Italy, [15] [16] [17] indicating a need for routine monitoring across provinces/insurance providers. We recognize that if histology is not classified consistently across provinces, then analyses by histology may be subject to measurement error and bias, contributing to the observed variable regional survival rates. The data did suggest possible variation in histology classification across regions. For example, British Columbia has a much higher proportion of diffuse astrocytomas and a much lower proportion of GBM than the rest of the country. It is possible that the BC survival rates reflect more advanced GBM tumours (classified as GBM) and less advanced GBM tumours (classified in the diffuse astrocytoma category) that would lower the estimated survival rates in both categories. Ontario has a much lower proportion of diffuse astrocytomas and a higher proportion of all other tumours. It is possible that some diffuse astrocytomas were classified into the all other tumours category, which could distort the true survival rates of both categories. The variation in microscopic confirmation, particularly for "all others" and gliomas (NOS) categories, also suggests some diagnostic variation which would be reflected in the histological classifications. Further assessment is needed to understand the variation in classification across regions. Going forward, surveillance data may need to incorporate the new molecular classification systems emerging for this type of information, which is expected to be increasingly clinically relevant. 18 As the most populated provinces -Ontario and Quebec -tended to have the better survival rates, one might speculate that providing patient care for a rare disease is more effective when the number of patients is larger; but the better survival rates for the mixed tumours with oligo features outside of Ontario suggests that other health system factors may also be at play. Provinces with populations over large geographic regions may have urban/rural or socio-economic level factors that indirectly influence disease outcomes that have not been addressed in our analyses.
The international literature on overall brain cancer survival comes from a large number of regions: Europe, the UK, the Nordic countries, Australia, the US and Korea, and tends to be consistent in reporting improved survival rates beginning in the 1970s [3] [4] [5] [6] [7] [8] through to the present. 19 In Canada, an improvement in survival rates for brain cancer patients between 1967 and 1986 was reported in the province of Saskatchewan which was attributed to patients under the age of 65 years. 8 In contrast, the UK reported an unexpected decline in survival during the late 1980s and 90s, with better survival rates emerging in males and younger age groups a decade later. 20 Histology-specific analysis such as that reported here has begun to explain some of these patterns by age and is needed to monitor changes in the histology-specific treatments now available. A recent analysis of GBM survival in the US suggests that the survival rates for these tumours did not progress much in the past three decades, 21 21 Survival data on a histology-specific basis have not been available for the Canadian population previously. 1 The ranking of these Canadian survival rates by histology is similar to that reported in CBTRUS for US data between 2005 and 2009. 22 The survival rates reported here are lower than those reported in the US for all histology groups. As noted above, there are differences in patient access to health insurance, access to care, clinical care guidelines and socio-cultural factors that may influence physician and patient decisions, reflecting these between-country survival differences. These data within Canada suggest the need to prioritize how to best approach implementing current evidence to improve brain cancer patient survival within Canada. CONCLUSION : Ces données sont conformes à celles d'études antérieures où l'on a observé des taux de survie supérieurs chez les jeunes patients, chez les femmes et pour les tumeurs mixtes (oligo-astrocytomes). Il faudrait pousser la recherche sur les raisons sous-jacentes de la variation observée des taux de survie par région afin d'améliorer le pronostic du cancer du cerveau dans la population de patients au Canada.
